

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/668,075	09/22/2003	Stephen A. Mamchur	4021.001	1250
73468 7590 971072010 HODES, PESSIN & KATZ , P.A 901 DULANEY VALLEY ROAD , SUITE 400			EXAMINER	
			SCHLIENTZ, NATHAN W	
BALTIMORE, MD 21204			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			07/07/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/668,075	MAMCHUR, STEPHEN A.	
Examiner	Art Unit	
Nathan W. Schlientz	1616	

The MAILING DATE of this commun.	cation appears on the cover sheet with the correspondence address
THE REPLY FILED 10 June 2010 FAILS TO PLACE	E THIS APPLICATION IN CONDITION FOR ALLOWANCE.
application, applicant must timely file one of t application in condition for allowance; (2) a N	prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this he following replies: (1) an amendment, affidavit, or other evidence, which places the otice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request noe with 37 CFR 1.114. The reply must be filed within one of the following time
The period for reply expiresmonths fr	om the mailing date of the final rejection.
 The period for reply expires on: (1) the mailing no event, however, will the statutory period for 	i date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In reply expire later than SIX MONTHS from the mailing date of the final rejection, property or (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO.
Extensions of time may be obtained under 37 CFR 1.136 have been filed is the date for purposes of determining th under 37 CFR 1.17(a) is calculated from: (1) the expiration	(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee e period of extension and the corresponding amount of the fee. The appropriate extension fee in date of the shortlened statutory period for reply originally set in the final Office action; or (2) as the Office later than three months after the mailing date of the final rejection, even if timely filled.
 The Notice of Appeal was filed on 15 March: date of filing the Notice of Appeal (37 CFR 4) 	2010. A brief in compliance with 37 CFR 41.37 must be filed within two months of the 1.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal reply must be filed within the time period set forth in 37 CFR 41.37(a).
 The proposed amendment(s) filed after a fin 	al rejection, but prior to the date of filing a brief, will not be entered because
	re further consideration and/or search (see NOTE below);
(b) They raise the issue of new matter (see	
appeal; and/or	ication in better form for appeal by materially reducing or simplifying the issues for
	canceling a corresponding number of finally rejected claims.
NOTE: <u>See Continuation Sheet</u> . (See	
	37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
 Applicant's reply has overcome the following 	
filed amendment canceling the non-allowable	
how the new or amended claims would be re The status of the claim(s) is (or will be) as fol	
Claim(s) allowed: Claim(s) objected to:	
Claim(s) rejected to: Claim(s) rejected: <u>123-138,140-158 and 160-</u> Claim(s) withdrawn from consideration: <u>139 and 160-</u>	
AFFIDAVIT OR OTHER EVIDENCE	
	nal action, but before or on the date of filing a Notice of Appeal will not be entered g of good and sufficient reasons why the affidavit or other evidence is necessary and 6(e).
entered because the affidavit or other eviden showing a good and sufficient reasons why it	date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be ce failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
	n explanation of the status of the claims after entry is below or attached.
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been of See Continuation Sheet.	onsidered but does NOT place the application in condition for allowance because:
Note the attached Information Disclosure St Other:	atement(s). (PTO/SB/08) Paper No(s)
/Johann R. Richter/ Supervisory Patent Examiner, Art Unit 1616	7/05/10

Continuation of 3. NOTE: Applicant's amendment to claim 160 would require further search and/or consideration. Claim 160 was amended to state "obtaining a plurally of concentrated liquid reagent compositions, each comprising one or more steroid hormone(s) dissolved in one or more solvent(s)"... and compounding "a plurality of said concentrated reagent composition(s) into said pharmaceutical product". However, this limitation was not previously considered and would require further search and/or consideration since previously the method only required obtaining one concentrated reagent composition in a solvent and compounding said one concentrated reagent composition in the a pharmaceutical product.

As noted above, newly proposed claims 123, 125-132, 134, 135, 137, 140 and 164 would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claims.

Continuation of 11, does NOT place the application in condition for allowance because: As noted above, the claim amendment to claim 160 would require further search and/or consideration. It is noted that Muni teaches a kit containing three or more active agents in separate containers and a base in a separate container (col. 3, ln. 10 to col. 4, ln. 40). Muni further teaches that the active agents may be dissolved in a suspending agent prior to mixing with the base (col. 11, ln. 4-33). Therefore, Muni teaches dissolving the active agents in a suspending agent in the form of a concentrate, and compounding the active with a base in order to fill a prescribing.